[CAS NO. 59277-89-3] Acyclovir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [59277-89-3]

Catalog

HY-17422

Brand

MCE

CAS

59277-89-3

DESCRIPTION [59277-89-3]

Overview

MDL	MFCD00057880
Molecular Weight	225.20
Molecular Formula	C8H11N5O3
SMILES	O=C1NC(N)=NC2=C1N=CN2COCCO

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

Summary

Acyclovir (Aciclovir) is a potent, orally active antiviral agent. Acyclovir has antiherpetic activity with IC ₅₀ values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2 , respectively. Acyclovir induces cell cycle perturbation and apoptosis . Acyclovir prevents bacterial infections during induction therapy for acute leukaemia ^[1] ^[2] ^[3] ^[4] .

IC50 & Target

HSV-1

0.85 μM (IC ₅₀ )

HSV-1

HSV-2

0.86 μM (IC ₅₀ )

In Vitro

Acyclovir (Aciclovir, 3-100 µM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) reduces cell viability in a dose- and time-dependent ^[1] .
Acyclovir (Aciclovir, 10-100 µM; 24-72 hours; Jurkat cells) blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner ^[1] .
Acyclovir (Aciclovir, 10-100 µM; 24-72 hours; Jurkat cells) induces apoptosis through activates caspase-3 and presences nuclear DNA fragmentation ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	Jurkat, U937 and K562 leukemia cells
Concentration:	3, 10, 30 and 100 µM
Incubation Time:	24, 48 and 72 hours
Result:	Showed a dose- and time-dependent reduction of cell viability.

Apoptosis Analysis ^[3]

Cell Line:	Jurkat cells
Concentration:	10 and 100 µM
Incubation Time:	24, 48 and 72 hours
Result:	Increased of caspase-3 activity and cleavaged the internucleosomal DNA.

Cell Cycle Analysis ^[1]

Cell Line:	Jurkat cells
Concentration:	10 and 100 µM
Incubation Time:	24, 48 and 72 hours
Result:	Revealed a dose-dependent accumulation of cells in S phase after 24 and 48 h. Showed a dose-dependent increase of the sub-G1 hypodiploid peak after 72 h.

In Vivo

Acyclovir (20 mg/kg; p.o.; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Specific-pathogen-free BALB/c mice (7-week-old) infected with HSV-1 ^[1]
Dosage:	20 mg/kg
Administration:	Oral administration; three times daily; for 10 days
Result:	Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05589688	University Hospital, Toulouse	Obesity	November 2022	Phase 1
NCT05313828	Sohag University	Corneal Ulcer	March 18, 2022
NCT00808405	University of Washington\|National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health (NIH)	Genital Herpes	January 2009	Not Applicable
NCT02583594	Genzyme, a Sanofi Company\|Sanofi	Progressive Multiple Sclerosis	December 6, 2015	Phase 1
NCT00362297	University of Washington	Genital Herpes	September 2006	Phase 4
NCT00491426	Duke University\|Pediatric Pharmacology Research Units Network	Infection	January 2006
NCT00000985	National Institute of Allergy and Infectious Diseases (NIAID)	Herpes Simplex\|HIV Infections		Phase 3
NCT00194519	University of Washington\|Bill and Melinda Gates Foundation	HIV Infection\|Herpes Simplex, Genital\|Sexually Transmitted Diseases	November 2004	Phase 3
NCT02977533	Sanofi	Progressive Multiple Sclerosis	December 1, 2016	Phase 1
NCT00371592	National Institute of Allergy and Infectious Diseases (NIAID)\|Comprehensive International Program of Research on AIDS	HIV Infections\|Herpesvirus 2, Human	September 2006	Phase 2
NCT00405821	National Institute of Allergy and Infectious Diseases (NIAID)\|University of Washington\|Johns Hopkins University\|Translational Genomics Research Institute\|National Institutes of Health Clinical Center (CC)	HIV Infections\|Herpes Genitalis	November 2006	Phase 2
NCT01729767	Tehran University of Medical Sciences	Meniere´s Disease	August 2011	Phase 2\|Phase 3
NCT02053142	University of North Carolina, Chapel Hill\|National Institute of Allergy and Infectious Diseases (NIAID)	Ulcers of Female Genital Organs	January 2009	Not Applicable
NCT00723229	University of Washington\|National Institutes of Health (NIH)	Genital Herpes	August 2008	Phase 4
NCT00002290	Glaxo Wellcome\|NIH AIDS Clinical Trials Information Service	HIV Infections		Not Applicable
NCT05429151	Sohag University	Acyclovir and Candida Antigen in Treatment of Plantar Wart	June 13, 2022	Phase 4
NCT05098938	Bayer	Recurrent Herpes Labialis	November 23, 2021	Phase 3
NCT05452928	Jacob Bodilsen\|Aalborg University Hospital	Herpes Simplex 2\|Meningitis, Viral	October 1, 2022	Phase 4
NCT00942084	Phillip Brian Smith\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|Duke University	Herpes Simplex Virus\|Neonatal Sepsis	September 2011	Phase 1
NCT00045292	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Cancer	April 2002	Phase 3
NCT00000139	National Eye Institute (NEI)	Keratitis, Herpetic\|Ocular Herpes Simplex\|Herpes Simplex	October 1992	Phase 3
NCT00527618	University of Washington\|GlaxoSmithKline	Genital Herpes\|HIV Infection	December 2007	Phase 4
NCT00000712	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 2
NCT00001010	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 1
NCT04988646	PT. Kimia Farma (Persero) Tbk\|PT Pharma Metric Labs	Drug Use	February 21, 2020	Not Applicable
NCT03831165	University of Sao Paulo General Hospital	Genital Herpes	September 2, 2015	Phase 4
NCT00031447	National Institute of Allergy and Infectious Diseases (NIAID)	Herpes Simplex	August 1999	Phase 3
NCT03626376	NYU Langone Health	Herpes Simplex Virus Keratitis	December 10, 2019	Phase 4
NCT02328469	University Medical Centre Ljubljana\|Slovenian Research Agency\|University of Ljubljana School of Medicine, Slovenia\|Harvard University	Aseptic Meningitis	June 2014
NCT00230867	Transport Pharmaceuticals	Herpes Labialis	April 2005	Phase 2
NCT05324904	Assiut University	Plantar Wart	October 2022	Not Applicable
NCT00004644	National Center for Research Resources (NCRR)\|National Institute of Allergy and Infectious Diseases (NIAID)\|Office of Rare Diseases (ORD)	Herpes Simplex	February 1995	Phase 1\|Phase 2
NCT03389191	Xiaomin Zhang\|Tianjin Medical University	Uveitis	January 2017	Not Applicable
NCT03368664	Genzyme, a Sanofi Company\|Sanofi	Multiple Sclerosis	October 24, 2017	Phase 3
NCT02282826	Genzyme, a Sanofi Company\|Sanofi	Progressive Multiple Sclerosis	October 2014	Phase 1
NCT00002186	Shaman Pharmaceuticals\|NIH AIDS Clinical Trials Information Service	Herpes Simplex\|HIV Infections		Not Applicable
NCT00006135	National Center for Research Resources (NCRR)\|University of Alabama at Birmingham	Herpes Simplex	June 1997	Phase 3
NCT00495716	University of Washington\|National Institute of Allergy and Infectious Diseases (NIAID)	Genital Herpes	January 2008	Phase 4
NCT02483182	Shulov Innovate for Science Ltd. 2012	Herpes Labialis	September 2015	Phase 2
NCT02349828	Southern Illinois University	Herpes Simplex	September 2015	Phase 2\|Phase 3
NCT02047253	University of Alabama at Birmingham\|Amgen	Metastatic Castration-resistant Prostate Cancer	April 2014	Phase 2
NCT00001038	National Institute of Allergy and Infectious Diseases (NIAID)\|Glaxo Wellcome	Cytomegalovirus Infections\|HIV Infections		Phase 3
NCT02152358	Assistance Publique Hopitaux De Marseille	Viral Pneumonia	March 2014	Phase 4
NCT02711267	Medical University of Graz\|Joanneum Research Forschungsgesellschaft mbH	Dermatologic Disorders	January 2014	Not Applicable
NCT01281007	EMS	GENITAL HERPES	July 2012	Phase 3
NCT00362596	Centers for Disease Control and Prevention\|Ministry of Health, Thailand	HIV\|Herpes	January 2005	Phase 4
NCT00076232	National Institute of Allergy and Infectious Diseases (NIAID)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|National Institute on Drug Abuse (NIDA)\|National Institute of Mental Health (NIMH)	HIV Infections\|HIV Seronegativity\|Herpes Genitalis	April 2005	Phase 3
NCT00002026	Glaxo Wellcome\|NIH AIDS Clinical Trials Information Service	Leukoplakia, Hairy\|HIV Infections		Not Applicable
NCT00061945	National Cancer Institute (NCI)	Acute Undifferentiated Leukemia\|B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Childhood Acute Lymphoblastic Leukemia\|L1 Adult Acute Lymphoblastic Leukemia\|L1 Childhood Acute Lymphoblastic Leukemia\|L2 Adult Acute Lymphoblastic Leukemia\|L2 Childhood Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia\|T-cell Adult Acute Lymphoblastic Leukemia\|T-cell Childhood Acute Lymphoblastic Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Childhood Acute Lymphoblastic Leukemia	June 2003	Phase 1\|Phase 2
NCT01833143	Memorial Sloan Kettering Cancer Center\|Millennium Pharmaceuticals, Inc.	Non-Small Cell Lung Cancer	April 11, 2013	Phase 2
NCT01653509	GlaxoSmithKline\|Labtec GmbH	Herpes Labialis	July 2012	Phase 1
NCT00002000	Glaxo Wellcome\|NIH AIDS Clinical Trials Information Service	Herpes Simplex\|HIV Infections		Not Applicable
NCT00467662	Hadassah Medical Organization	Reccurent Herpes Labialis		Phase 4
NCT00000138	National Eye Institute (NEI)	Keratitis, Herpetic\|Ocular Herpes Simplex	May 1989	Phase 3
NCT00001115	National Institute of Allergy and Infectious Diseases (NIAID)	Herpes Simplex\|HIV Infections		Not Applicable
NCT00361881	Medivir	Herpes Labialis	July 2006	Phase 3
NCT01327144	EMS	Herpes Zoster	June 2012	Phase 3
NCT00209352	Fred Hutchinson Cancer Center\|Burroughs Wellcome\|National Institutes of Health (NIH)	VZV Infection After Bone Marrow Transplantation	June 1985	Phase 3
NCT04476186	Dalia Mahran\|assistant professor Ghada M. Khafagy\|Dr. Marwa Diaaeldeen Abbass Hasan\|Prof. Dr. Emad Taha Abd-Elahim Ebiad\|Assiut University	Molluscum Contagiosum	June 15, 2020	Not Applicable
NCT01026454	University of Washington	HSV Infection\|HIV Infection	February 2010	Phase 4
NCT00031460	National Institute of Allergy and Infectious Diseases (NIAID)	Herpes Simplex	December 1997	Phase 3
NCT00002084	Glaxo Wellcome\|NIH AIDS Clinical Trials Information Service	Herpes Simplex\|HIV Infections		Not Applicable
NCT00078559	University of Wisconsin, Madison\|Immune Tolerance Network (ITN)	Kidney Transplantation\|Kidney Disease	November 2003	Phase 1\|Phase 2
NCT00004757	National Center for Research Resources (NCRR)\|National Institute of Allergy and Infectious Diseases (NIAID)\|Office of Rare Diseases (ORD)	Herpes Simplex	August 1992	Phase 3
NCT00769314	Onxeo	Herpes Labialis	May 2007	Phase 3
NCT02205489	Genzyme, a Sanofi Company\|Sanofi	Relapsing-remitting Multiple Sclerosis	October 2014	Phase 4
NCT02151240	Cttq\|Peking University People´s Hospital	Herpes Zoster	May 2014	Phase 4
NCT00495573	University of Washington\|National Institutes of Health (NIH)	Genital Herpes	June 2007
NCT00164424	Centers for Disease Control and Prevention\|London School of Hygiene and Tropical Medicine\|National Institute for Communicable Diseases, South Africa	HIV Infections\|Ulcer\|Herpes Simplex	March 2005	Phase 2\|Phase 3
NCT05127395	Methodist Health System	HSV Encephalitis	March 31, 2021
NCT03443869	Merck Sharp & Dohme LLC	CMV Disease	May 3, 2018	Phase 3
NCT00002315	Glaxo Wellcome\|NIH AIDS Clinical Trials Information Service	HIV Infections\|Chickenpox		Phase 3
NCT00000693	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT02073097	Case Comprehensive Cancer Center	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma	January 28, 2015	Phase 1\|Phase 2
NCT01257074	EMS	Herpes Labialis	February 2012	Phase 3
NCT03159845	Azienda Ospedaliero, Universitaria Pisana	Stem Cell Transplant Complications	January 1, 2014	Phase 2
NCT03656965	Kuwait Cancer Control Center	Drug Use for Unapproved Schedule	May 1, 2018	Phase 3
NCT00209313	Fred Hutchinson Cancer Center\|Institute for the Development of Africa	HIV-1 and HSV-2 Coinfection\|HIV Infections	March 2005	Phase 2\|Phase 3
NCT00330018	Hadassah Medical Organization	Bone Marrow Transplantation\|Cytomegalovirus	February 2006	Phase 3
NCT00158483	French National Agency for Research on AIDS and Viral Hepatitis	Ulcer\|Herpes Genitalis	May 2003	Phase 2
NCT00000953	National Institute of Allergy and Infectious Diseases (NIAID)\|Bristol-Myers Squibb\|Glaxo Wellcome	HIV Infections\|Chickenpox		Phase 2
NCT04132115	Azienda Sanitaria-Universitaria Integrata di Udine	Therapeutic Drug Monitoring\|Subarachnoid Hemorrhage\|Intracerebral Hemorrhage	October 1, 2019
NCT02265913	Padagis LLC	Herpes Labialis	October 6, 2014	Phase 3
NCT00469300	Transport Pharmaceuticals	Herpes Labialis	April 2007	Phase 2
NCT00855309	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Herpes Simplex	November 2008	Phase 3
NCT02255734	Yung Shin Pharm. Ind. Co., Ltd.	Healthy	April 2014	Phase 4
NCT00735761	Medivir	Herpes Labialis	December 2006	Phase 3
NCT00006132	National Center for Research Resources (NCRR)\|University of Alabama at Birmingham	Herpes Simplex	June 1997	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL ( 222.02 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.4405 mL	22.2025 mL	44.4050 mL
5 mM	0.8881 mL	4.4405 mL	8.8810 mL
10 mM	0.4440 mL	2.2202 mL	4.4405 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-

2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one

Acycloguanosine

9-(2-Hydroxyethoxymethyl)guanine

Acyclovir

Aciclovir

Zovirax

BW 248U

ACV

Gerpevir

Herpevir

Avirase

Virorax

Acicloftal

Cargosil

Vipral

Poviral

Zyclir

Acyclo V

Wellcome 248U

NSC 645011

BioVir I

BioVir II

Virovir

Novirus

Lovir

Rouz-Aciclovir

Zirax

Virless

Virax

Vicclox

Acivir

Axiluowei

2-Amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one

2-Amino-9-(2-hydroxy-ethoxymethyl)-1,9-dihydro-purin-6-one

2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one

2-Amino-9-(2-hydroxy-ethoxymethyl)-3,9-dihydro-purin-6-one

2-Amino-9-[(2-hydroxyethoxy)methyl]-9H-purin-6-ol

2-Amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one